Results 21 to 30 of about 39,378 (264)

Advanced pancreatic cancer: the standard of care and new opportunities

Oncology Reviews, 2018
Presentation of pancreatic cancer is localized, locally advanced or metastatic. With the later represented the main bulk (more than 80%). Despite the significant innovation in molecular analysis and therapeutic approach in many types of cancer in the ...
Amrallah A. Mohammad
doaj   +1 more source

Treatment of Resectable and Locally Advanced Pancreatic Cancer [PDF]

Cancer Control, 2000
Pancreatic cancer is the fifth leading cause of cancer death in the United States, with an overall 5-year survival rate of less than 5%. A minority of patients are candidates for surgical resection, but most treatment strategies focus on palliative care.We discuss strategies in the diagnosis and treatment of resectable and locally advanced pancreatic ...
B W, Kuvshinoff, M P, Bryer
openaire   +2 more sources

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer

Case Reports in Oncology, 2014
The prognosis of patients with locally advanced pancreatic cancer can be improved if secondary complete (R0) resection is possible. In patients initially staged as unresectable this may be achieved with neoadjuvant treatment which is usually ...
Volker Kunzmann, Ken Herrmann, Christina Bluemel, Markus Kapp, Ingo Hartlapp, Ulrich Steger   +5 more
doaj   +1 more source

Arterial reconstruction by anastomosis of left gastric artery and superior mesenteric artery for locally advanced pancreatic carcinoma

Journal of Vascular Surgery Cases and Innovative Techniques, 2019
We report the case of a 61-year-old man with pancreatectomy with arterial resection and reconstruction and extended lymph node dissection because of locally advanced pancreatic cancer.
Ling Liu, PhD, Changku Jia, MD, Sunbing Xu, PhD, Minwei Shen, MD   +3 more
doaj   +1 more source

The Treatment of Locally Advanced Pancreatic Cancer: A Practice Guideline

Canadian Journal of Gastroenterology, 2003
BACKGROUND: Pancreatic adenocarcinoma is the fourth most common cause of adult cancer death. About 50% of patients present with metastatic disease, 20% with resectable disease and the remaining 30% of patients are diagnosed with incurable, locally ...
Craig C Earle, Olusegun Agboola, Jean Maroun, Lisa Zuraw, Cancer Care Ontario Practice Guidelines Initiative’s Gastrointestinal Cancer Disease Site Group   +4 more
doaj   +1 more source

Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial

Trials, 2011
Background Pancreatic cancer is the fourth leading cause of cancer death in the United States. Surgery offers the only chance for cure. However, less than twenty percent of patients are considered operative candidates at the time of diagnosis.
Toomey Mary, Walker Melissa, Steinberg Seth M, Langan Russell C, Ripley R Taylor, Pandalai Prakash, Davis Jeremy L, Levy Elliot, Avital Itzhak   +8 more
doaj   +1 more source

Successful conversion surgery of distal pancreatectomy with celiac axis resection (DP-CAR) with double arterial reconstruction using saphenous vein grafting for locally advanced pancreatic cancer: a case report

Surgical Case Reports, 2020
Background Pancreatic cancer is a disease with a poor prognosis, requiring multidisciplinary treatment combining chemotherapy and surgery for effective management.
Yoshiki Murase, Daisuke Ban, Aya Maekawa, Shuichi Watanabe, Yoshiya Ishikawa, Keiichi Akahoshi, Kosuke Ogawa, Hiroaki Ono, Atsushi Kudo, Toshifumi Kudo, Shinji Tanaka, Minoru Tanabe   +11 more
doaj   +1 more source

Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study

BMC Cancer, 2020
Background The current study aimed to evaluate the outcomes of patients with unresectable non-metastatic locally advanced pancreatic adenocarcinoma (LAPA) who did not benefit from resection considering the treatment strategy in the clinical settings ...
Jonathan Garnier, Jacques Ewald, Ugo Marchese, Marine Gilabert, Simon Launay, Laurence Moureau-Zabotto, Flora Poizat, Marc Giovannini, Jean-Robert Delpero, Olivier Turrini   +9 more
doaj   +1 more source

Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities?

BMC Surgery, 2023
Background The treatment of borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) has evolved with a wider application of neoadjuvant chemotherapy (NACHT).
Luís Filipe Abreu de Carvalho, Filip Gryspeerdt, Niki Rashidian, Kobe Van Hove, Lambertine Maertens, Suzane Ribeiro, Anne Hoorens, Frederik Berrevoet   +7 more
doaj   +1 more source

Advances of pathological complete response after neoadjuvant therapy for pancreatic cancer

Journal of Pancreatology, 2019
. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis. Only 15% to 20% of patients present with a primarily resectable tumor at the time of diagnosis.
Lingdi Yin, MD, Yi Miao, MD, PhD, Jun Yu, MD, PhD   +2 more
doaj   +1 more source